Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Jordan Gauthier, MD MSc, Cassie Chou, MDPhD, Alexandre V. Hirayama, MD, Salvatore Fiorenza, MBBS, PhD, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Tinh-Doan Phi, BSc, Rachel Steinmetz, BSc, Abby Jamieson, BSc, Delaney R Kirchmeier, BSc, Henna N Di, BSc, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140120

Published: 2020

Journal Articles

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

Cassie Chou, MD PhD, Simon Fraessle, Rachel Steinmetz, BSc, Reed M. Hawkins, BS, Tinh-Doan Phi, BS, Dirk Busch, Takahiro Miyazaki, Mario Q. Marcondes, MD PhD, Stanley R. Riddell, MD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 2866.

https://doi.org/10.1182/blood-2019-125960

Published: 2019

Journal Articles

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Evandro D. Bezerra, MD, Jordan Gauthier, MD MSc, Alexandre V. Hirayama, MD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 201.

https://doi.org/10.1182/blood-2019-123807

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Andrew J. Cowan, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD PhD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, Qian Vicky Wu, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Damian J. Green, MD

Blood (2019) 134 (Supplement_1): 204.

https://doi.org/10.1182/blood-2019-129405

Published: 2019

Journal Articles

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Damian J. Green, MD, Margot Pont, PhD, Andrew J. Cowan, MD, Gabriel O Cole, Blythe Duke Sather, PhD, Anne M Nagengast, RN, Xaoling Song, Sushma Thomas, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD

Blood (2019) 134 (Supplement_1): 1856.

https://doi.org/10.1182/blood-2019-129582

Published: 2019

Journal Articles

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Blood (2018) 132 (Supplement 1): 281.

https://doi.org/10.1182/blood-2018-99-110561

Published: 2018

Journal Articles

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Blood (2018) 132 (Supplement 1): 299.

https://doi.org/10.1182/blood-2018-99-111061

Published: 2018

Journal Articles

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

Damian J. Green, MD, Margot Pont, PhD, Blythe Duke Sather, PhD, Andrew J. Cowan, MD, Cameron J. Turtle, MBBS, PhD, Brian G. Till, MD, Anne M Nagengast, RN, Edward N. Libby, III, MD, Pamela S. Becker, MD, David G. Coffey, MD, Sherilyn A. Tuazon, MD, Brent Wood, MD PhD, Michelle Blake, PhD, Melissa Works, PhD, Bruce S Thompson, PhD, Ted Gooley, PhD, Frederick R. Appelbaum, MD, David G. Maloney, MD PhD, Stanley R. Riddell, MD

Blood (2018) 132 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2018-99-117729

Published: 2018

Journal Articles

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Jordan Gauthier, MD, Alexandre V. Hirayama, MD, Kevin A. Hay, MDFRCPC, MSc, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Tinh-Doan Phi, BS, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, Ryan D. Cassaday, MD, Utkarsh H. Acharya, DO, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1415.

https://doi.org/10.1182/blood-2018-99-111528

Published: 2018

Journal Articles

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2018-99-116745

Published: 2018

Journal Articles

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2018-99-115126

Published: 2018

Journal Articles

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Cameron J. Turtle, MBBS, PhD, Kevin A. Hay, MD FRCPC, MSc, Laila-Aicha Hanafi, PhD, Juliane Gust, MDPhD, W. Conrad Liles, MDPhD, José A. López, MD, Junmei Chen, PhD, Dominic W. Chung, PhD, Mark M Wurfel, MDPhD, Susanna Harju-Baker, PhD, Hasan Ozpolat, MD, Daniel Li, PhD, David Myerson, MDPhD, Luis F. Gonzalez-Cuyar, MD, Cecilia Yeung, MD, Kathleen R. Fink, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD

Blood (2017) 130 (Supplement 1): 805.

https://doi.org/10.1182/blood.V130.Suppl_1.805.805

Published: 2017

Journal Articles

NaïVe T Cell Depletion of PBSC Grafts Results in Very Low Rates of Chronic Gvhd and High Survival

Marie Bleakley, MDPhD, Ted A. Gooley, PhD, Barbara Hilzinger, RN, Stanley R Riddell, MD, Warren D Shlomchik, MD

Blood (2016) 128 (22): 668.

https://doi.org/10.1182/blood.V128.22.668.668

Published: 2016

Journal Articles

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G Maloney, MD PhD

Blood (2016) 128 (22): 56.

https://doi.org/10.1182/blood.V128.22.56.56

Published: 2016

Journal Articles

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

Cameron J Turtle, MBBS, PhD, Kevin A Hay, MDFRCPC, MSc, Gust Juliane, MD PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G. Maloney, MD PhD

Blood (2016) 128 (22): 1852.

https://doi.org/10.1182/blood.V128.22.1852.1852

Published: 2016

Journal Articles

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 3773.

https://doi.org/10.1182/blood.V126.23.3773.3773

Published: 2015

Journal Articles

Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab

Gregory A. Rufener, Philip Olsen, Sang Yun Lee, PhD, Michael C Jensen, MD, Ajay K. Gopal, MD, Barbara Pender, MS, Damian J. Green, MD, David G. Maloney, MD PhD, Stanley R. Riddell, MD, Oliver W Press, MD PhD, Brian G. Till, MD

Blood (2015) 126 (23): 4428.

https://doi.org/10.1182/blood.V126.23.4428.4428

Published: 2015

Journal Articles

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Leslie Popplewell, MD, Xiuli Wang, PhD, Araceli Naranjo, BS, Suzette Blanchard, PhD, Jamie Wagner, BS, ChingLam Wong, BS, Ryan Urak, MS, Wen-Chung Chang, MS, Samer K Khaled, MD, Tanya Siddiqi, MD, Elizabeth E. Budde, MD PhD, Jingying Xu, PhD, Brenda Chang, BS, Sandra H. Thomas, PhD, Stanley R. Riddell, MD, Christine Brown, PhD, Michael C Jensen, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 930.

https://doi.org/10.1182/blood.V126.23.930.930

Published: 2015

Journal Articles

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Cameron J Turtle, MBBS, PhD, Carolina Berger, MD, Daniel Sommermeyer, PhD, Laila-Aicha Hanafi, PhD, Barbara Pender, MS, Emily M Robinson, BS, Katherine Melville, Tanya M Budiarto, BSc, Natalia N Steevens, Colette Chaney, RN, Sindhu Cherian, MD, Brent L Wood, MD PhD, Lorinda Soma, MD, Xueyan Chen, MD PhD, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R. Riddell, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 184.

https://doi.org/10.1182/blood.V126.23.184.184

Published: 2015

Journal Articles

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

Cameron J Turtle, MBBS, PhD, Daniel Sommermeyer, PhD, Carolina Berger, MD, Michael Hudecek, MD, David M Shank, Natalia N Steevens, BS, Tanya M Budiarto, BSc, Mandana Karimi, MS, Colette N Chaney, RN, Anna Marie DeVito, RN, Shelly Heimfeld, PhD, Michael C Jensen, MD, Stanley R Riddell, MD, David G Maloney, MDPhD

Blood (2014) 124 (21): 384.

https://doi.org/10.1182/blood.V124.21.384.384

Published: 2014

NARROW

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

NaïVe T Cell Depletion of PBSC Grafts Results in Very Low Rates of Chronic Gvhd and High Survival

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia

Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab

Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only